Three different ATRX KO high-grade glioma cell lines showed sensitivity to pazopanib and three additional RTKi (sorafenib, nintedanib, and sunitinib), all of which target PDGFR and other RTKs. Here, PDGFRB is linked to central nervous system cancer.